Prefilled syringe eliminates the need to reconstitute separate vials prior to administration and simplifies the vaccine process.

The U.S. Food and Drug Administration has approved GSK's prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted) for the prevention of shingles (herpes zoster).

MONDAY, July 21, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved a prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted) for the ...

The prefilled syringe presentation is licensed in the United States for immunization of adults 50 years and older, as well as those aged 18 years and older who are or will be at increased risk for ...

The prefilled syringe presentation of GSK’s shingles vaccine is also undergoing regulatory review by the European Medicines Agency (EMA), with filing acceptance received in January 2025, marking ...

The US Food and Drug Administration (FDA) has approved GSK's Shingrix vaccine (recombinant zoster vaccine or RZV) in a prefilled syringe presentation to prevent shingles (herpes zoster).

(Alliance News) - GSK PLC on Thursday said the prefilled syringe version of its vaccine Shingrix has been approved for use in the US for the prevention of shingles. The London-based drug maker ...

The FDA has approved a prefilled syringe option of Shingrix which will streamline administration of GSK’s herpes zoster vaccine for adult patients.

The company added that the prefilled syringe presentation of GSK's shingles vaccine is also undergoing regulatory review by the European Medicines Agency.

FDA approves Shingrix prefilled syringe: New format eliminates reconstitution step, simplifying shingles (herpes zoster) vaccine administration for healthcare providers. Same indications, easier ...

PHILADELPHIA, July 17, 2025--GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved a prefilled syringe presentation of SHINGRIX (Zoster Vaccine ...